Highly concordant coexpression of aromatase and estrogen receptor β in non–small cell lung cancer
Keiko Abe(The University of Tokyo), Hironobu Sasano(Tohoku University), Miki Mori(SHOWA Medical University), Yasuhiro Miki(Eli Lilly (Japan)), Takashi Suzuki(Tohoku University), Satoshi Suzuki, Yuki Kou(Tohoku University), Hiromichi Niikawa(Iwate Prefectural Central Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Masashi Koguchi(Tohoku University), Katsuhiko Ono(Kumamoto University), Hideaki Kakinuma(Tohoku University), Nobutaka Kudo(Tohoku University), Dean B. Evans(Novartis (Switzerland))
Cited by 67
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k